Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia
- 9 June 2015
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 30 (4) , 947-950
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A Case of 8p11 Myeloproliferative Syndrome with BCR-FGFR1 Gene Fusion Presenting with Trilineage Acute Leukemia/Lymphoma, Successfully Treated by Cord Blood TransplantationActa Haematologica, 2012
- Allogeneic Hematopoietic Stem Cell Transplantation for aBCR-FGFR1Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic LeukemiaCase Reports in Hematology, 2012
- Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeHaematologica, 2012
- t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: Report of a case treated with sorafenib and review of the literatureLeukemia Research, 2011
- 8p11 myeloproliferative syndrome: a reviewHuman Pathology, 2010
- Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorderBone Marrow Transplantation, 2009
- Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndromeBlood, 2007
- Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusionInternational Journal of Oncology, 2005
- PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderProceedings of the National Academy of Sciences, 2004
- Fusion of the BCR and the fibroblast growth factor receptor‐1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: The first fusion gene involving BCR but not ABLGenes, Chromosomes and Cancer, 2001